Suzuken Co., Ltd.

9987.T
Medical Distribution
2026/01/16 Updated
Market Cap: $2.7B (¥435.7B)
Stock Price: $39.89 (¥6,321)
Exchange Rate: 1 USD = ¥158.48

Notice Regarding the Status of Treasury Stock Acquisition

In December 2025, 370,700 common shares were acquired at a total value of ¥2,266,503,200, bringing the cumulative number of acquired shares to 3,575,600 and the total acquisition cost to ¥20,385,023,900.

Importance:
Page Updated: January 5, 2026
IR Disclosure Date: January 5, 2026

Key Figures

  • Number of Shares Acquired in December 2025: 370,700 shares
  • Total Acquisition Cost in December 2025: ¥2,266,503,200
  • Cumulative Treasury Stock Acquisition (As of December 30, 2025): 3,575,600 shares, ¥20,385,023,900

AI要約

Overview of Capital Policy

Suzuken Co., Ltd. acquired 370,700 common shares at a total cost of ¥2,266,503,200 through market purchases on the Tokyo Stock Exchange during the period from December 1 to December 30, 2025. As a result, as of December 30, 2025, the cumulative number of treasury stock acquired reached 3,575,600 shares, and the total acquisition cost amounted to ¥20,385,023,900. The acquisition of treasury stock is being conducted pursuant to a Board of Directors resolution announced on May 13, 2025, allowing up to 5,200,000 shares (7.21% of issued shares) with an acquisition cost cap of ¥26 billion.

Impact on Shareholders and Future Outlook

Treasury stock acquisitions are carried out through market purchases, with the ratio of treasury stock to issued shares permitted up to 7.21%. As of the end of December 2025, the number of shares acquired was 3,575,600, and further acquisitions are expected within the acquisition period through March 19, 2026. This is anticipated to enhance shareholder value and mitigate share dilution; however, detailed impacts of the acquisition status should be monitored through future disclosures.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.